How Mylan ended as a junior partner in its Pfizer deal

As the biopharma bull market reached its peak in 2015, a three-way acquisition battle raged across the generics sector, with Mylan chasing Perrigo while simultaneously trying to fend off Teva. At the time, the market value of the three drugmakers together was $130 billion.